Introduction
============

A keloid is defined as an overgrowth of pathological scar tissue that grows beyond the original boundaries of the wound, does not regress spontaneously and tends to recur despite treatment ([@b1-mmr-19-02-0919],[@b2-mmr-19-02-0919]). It can also spread to the surrounding skin by invasion ([@b3-mmr-19-02-0919]). The clinical feature of keloid is a raised growth, usually accompanied by pain and pruritus ([@b4-mmr-19-02-0919]). Since the mechanism and etiopathogenesis of keloids remain unknown, keloid therapy is very limited.

Tumor necrosis factor-stimulated gene-6 (TSG-6) was identified in differential screening of a cDNA library collected from tumor necrosis factor-treated human diploid FS-4 fibroblasts ([@b5-mmr-19-02-0919]). Multiple functions of TSG-6 have been proposed, including interacting with matrix-associated molecules or acting as an inflammatory factor ([@b6-mmr-19-02-0919],[@b7-mmr-19-02-0919]). However, current knowledge on the physiological function of TSG-6 remains limited. It has been reported to be critical in maintaining the physiological architecture of skin ([@b8-mmr-19-02-0919]). Furthermore, TSG-6 has potent anti-inflammatory properties, which have been investigated in several disease models, such as rheumatoid arthritis ([@b9-mmr-19-02-0919],[@b10-mmr-19-02-0919]). In our previous rabbit ear model of hypertrophic scarring, injection of TSG-6 protein into the wound resulted in reduced hypertrophic scar formation and anti-inflammatory effects during wound healing ([@b11-mmr-19-02-0919]). However, the role of TSG-6 in keloid remains unclear.

In the current study, a TSG-6 expression vector was constructed and stably transfected into human keloid fibroblasts (KFs). The effects of overexpression of TSG-6 on proliferation and apoptosis in KFs were determined. In addition, the potential mechanisms of the signaling pathway regulated via TSG-6 in KFs were investigated.

Materials and methods
=====================

### Ethics

The current study was approved by the institutional review board of Anhui Medical University (Hefei, China), and written informed consent was obtained from all patients prior to inclusion. The study was performed according to the principles of the Declaration of Helsinki.

### Keloid fibroblasts and cell culture

Ten patients were recruited from the First Affiliated Hospital of Anhui Medical University. The characteristics of participants with keloid in this study are listed in [Table I](#tI-mmr-19-02-0919){ref-type="table"}. Patients had received no previous treatment for keloid. KFs were isolated and cultured as previously described ([@b12-mmr-19-02-0919]). Cells were cultured in Dulbeccos modified Eagles medium (DMEM), L-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin and fetal calf serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). No morphological and biochemical differences were found with the passage.

### Lentiviral vector construction and packaging

Total RNA was extracted from KFs using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturers instructions. cDNA synthesis was conducted according to the RNA polymerase chain reaction (PCR) kit protocol (Takara Bio, Inc., Otsu, Japan). The TSG-6 cDNA (GenBank no. AJ421518) was amplified by PCR (Takara Bio, Inc.) from KF cDNA using the following oligonucleotide primers: Forward, 5′-GGAATTCATGATCATCTTAATTTACT-3; and reverse, 5′-CGGGATCCTAAGTGGCTAAATCTTCC-3. The cycling for PCR amplifying reaction was: Reverse transcription (RT) 50°C, 5 min for 1 cycle; RT inaction 95°C, 20 sec for 1 cycle; denaturing 95°C, 15 sec for 40 cycles; annealing 60°C, 60 sec for 40 cycles. Sequencing results were analyzed using Basic Local Alignment Search Tool (BLAST) from National Center for Biotechnology Information (Bethesda, MD, USA). The amplified DNA was digested by the enzymes *Eco*RI and *Bam*HI and ligated into lentiviral plasmid pLVX-Puro (Clontech Laboratories, Inc., Mountain View, CA, USA). Following transduction of DH5α-competent *E. coli*, the positive clones were selected for PCR identification and DNA sequencing. Clones containing the target plasmids were selected and named pLVX-Puro-TSG-6.

pLVX-Puro-TSG-6 was highly purified and extracted with endotoxin-free solution. pLVX-Puro-TSG-6 was then co-transfected into 293T cells (Clontech Laboratories, Inc.) with pHelper 1.0 (Biovector Science Lab, Inc., Beijing, China) and pHelper 2.0 (Biovector Science Lab, Inc.) and lentiviruses using Lipofectamine^®^ 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturers instructions. The 293T cells were cultured using Minimum Essential Media (MEM; Gibco; Thermo Fisher Scientific, Inc.). Cells were cultured at 37°C in 5% CO~2~. Cells were seeded at a concentration of 5×10^5^ cells/well in 6 well plates. The plasmids were mixed in a 1.5 ml Eppendorf tube with 1.5 µg Lentiviruses plus 1.5 µg packing vector (pLVX-Puro-TSG-6: pHelper 1.0: pHelper 2.0=5:3:2) and 125 µl MEM medium, then 5 µl Lipo in 125 µl MEM added. The Lipo and plasmids mixture was mixed and incubated for 20 min at 25°C. During the incubation of the Lipo and plasmids mixture, the culture medium of the 293T cells was replaced with fresh MEM medium. Then the transfection mixture was added to the well, and it was moved to an incubator at 37°C and 5% CO~2~. At 8 h following transfection, the medium was replaced with fresh growth medium. After culture for 48 h, the supernatant containing lentivirus particles was collected and centrifuged at 1,258 × g for 5 min, and cell debris was discarded. In order to obtain a high concentration of lentivirus, the supernatant was further filtered to remove cells and debris. The virus titer in 293T cells was determined by end-point dilution assay.

### Infection with recombinant lentiviruses

KFs in logarithmic growth phase were divided into three groups: pLVX-Puro-TSG-6 group, pLVX-Puro group and KFs group. In each group, 8×10^4^ cells were seeded into a 6-well plate and cultured in an incubator with 5% CO~2~ at 37°C for 24 h. Following adhesion, the supernatant was discarded, and 2 ml DMEM containing 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.) was added. Once the cells reached 30% confluence, the medium was removed. Subsequently, pLVX-Puro-TSG-6 or pLVX-Puro were added into the wells at multiplicity of infection of 10. Following the addition of 50 µl polybrene, DMEM containing 10% fetal calf serum was added to reach a total of 2 ml. For the KF group (2 wells), only 2 ml DMEM containing 10% fetal calf serum was added. Stable transfectants of pLVX-Puro-TSG-6 and pLVX-Puro were continuously selected using 2.5 µg/ml puromycin. Stable transfection was further confirmed by reverse transcription-PCR (RT-PCR) and western blot analysis.

### RNA isolation and RT-PCR

Levels of specific mRNAs in each group were assessed by RT-PCR. Total RNA was extracted using the Trizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Purified RNA (1 µg) was reverse transcribed using the RNA PCR Kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturers protocol. PCR primers are listed in [Table II](#tII-mmr-19-02-0919){ref-type="table"}. cDNA was amplified and quantified using the RT-PCR Kit and the following conditions: 94°C for 5 min, then 40 cycles consisting of 30 sec at 94°C, 30 sec at 54°C and 45 sec at 72°C, followed by incubation at 72°C for 10 min.

PCR products with UltraPure Ethidium bromide (EB; Invitrogen, Thermo Fisher Scientific, Inc.) were electrophoresed on a 2% agarose gel. An image of the gel was captured and the intensity of the bands was analyzed using Labworks software (UVP; LLC, Phoenix, AZ, USA). β-actin was used as the internal loading control.

### Western blot analysis

Total protein was prepared using RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific, Inc.) at freezing temperature (Cell Signaling Technology, Inc., Danvers, MA, USA). Protein concentration was measured using a bicinchoninic acid assay protein concentration kit (Pierce; Thermo Fisher Scientific, Inc.). Equal amounts of cell lysate (50 µg of protein) were boiled for 5 min and resolved by SDS-PAGE (12%), then electrophoretically transferred onto a nitro-cellulose membrane. The membrane was blocked with 5% non-fat dry milk in Tris-buffered saline with Tween (TBST) overnight at 4°C, then incubated with appropriate primary antibodies: TSG-6 (cat. no. ab128266; Abcam, Cambridge, MA, USA; 1:1,000); p21 (cat. no. 2947; Cell Signaling Technology, Inc.; 1:1,000); cyclin D1 (cat. no. 2978; Cell Signaling Technology, Inc.; 1:1,000); apoptosis regulator Bcl-2-associated X protein (Bax; cat. no. 5023; Cell Signaling Technology, Inc.; 1:1,000); apoptosis regulator B-cell lymphoma-2 (Bcl-2; cat. no. 2872; Cell Signaling Technology, Inc.; 1:1,000); caspase-3 (cat. no. 9662; Cell Signaling Technology, Inc.; 1:1,000); nuclear factor-κB (NF-κB; cat. no. 8242; Cell Signaling Technology, Inc.; 1:1,000); GAPDH (cat. no. 5174; Cell Signaling Technology, Inc.; 1:1,000); β-actin (cat. no. 4970; Cell Signaling Technology, Inc.; 1:1,000) in blocking buffer for 2 h at room temperature or 8--12 h at 4°C. Following washing with TBST, the membranes were then incubated with appropriate secondary antibody (goat anti-rabbit; cat. no. 7074; Cell Signaling Technology, Inc.; 1:10,000) for 3 h at room temperature. After washing with TBST, proteins were visualized using an enhanced chemiluminescence assay kit (Thermo Fisher Scientific, Inc.). Grey scale scanning was used to analyze relative expression by using Quantity One 1D Analysis software (version 4.4, Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### MTT assay

An MTT assay was performed to evaluate cell proliferation of pLVX-Puro-TSG-6 transfected cells, pLVX-Puro transfected cells and KFs. Single-cell suspensions (1×10^5^ cells/ml) were prepared for each group, and 100 µl cell suspension was seeded into 96-well plates and incubated at 37°C with 5% CO~2~ to form a monolayer. At 24 h, once cells had adhered, 10 µl MTT stock solution (Promega Corporation, Madison, WI, USA) was added to each well, and the plate was then incubated at 37°C for 4 h. The MTT stock solution was discarded and 10 µl MTT solvent was added to each well and incubated for 4 h at 37°C to allow the crystals to be fully dissolved. The OD values at 570 nm were determined and the experiment was repeated three times. Assay was also performed at 48, 72, 96 and 120 h after plating.

### Flow cytometry assay

Flow cytometry was performed to evaluate apoptosis and cell cycle arrest of the pLVX-Puro-TSG-6 transfected cells, pLVX-Puro transfected cells and KFs. Cells in each group were collected, digested with trypsin, washed with PBS three times, and centrifuged at 4°C for 5 min at 560 × g, and the supernatant was discarded. The cells were fixed with 70% ethanol at 4°C for ≥24 h and then washed with PBS twice, following removal of ethanol by centrifugation. Cell apoptosis was detected using Annexin V-FITC Apoptosis Staining/Detection kit (Abcam). Cells (1×10^5^) were collected by centrifugation 4°C for 5 min at 560 × g and re-suspended in 500 µl 1X binding buffer. Following incubation with 5 µl of Annexin V-fluorescein isothiocyanate (FITC) and 5 µl of propidium iodide (PI), the cells were maintained at room temperature for 5 min in the dark. Apoptosis was detected using a flow cytometer and analyzed with FlowJo 10.0.6 (FlowJo LLC, Ashland, OR, USA).

For cell cycle analysis, cells from each group were fixed in 70% ethanol for 1--3 h at 4°C. After washing with PBS, cells were collected with RNase A and stained with PI for 15 min at 37°C. Cell cycle was analyzed with the flow cytometer, and the distribution of all cell-cycle phases was determining with Modfit Software (BD Biosciences, Franklin Lakes, NJ, USA).

### Statistical analysis

All data are presented as the mean ± standard deviation. Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Tests for homogeneity of variance (Levenes test) and one-way analysis of variance procedures were performed, and followed by Turkeys multiple comparison post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Transfection efficiency

An 828 bp target gene fragment was obtained from agarose gel electrophoresis of a PCR product, the size of which was in accordance with TSG-6. The results suggested that TSG-6 gene was successfully cloned into the pLVX-Puro vector ([Fig. 1](#f1-mmr-19-02-0919){ref-type="fig"}). Agarose gel electrophoresis revealed the positive clones after infection, with 1,179 bp and 198 bp size bands for positive and negative transformants, respectively ([Fig. 2](#f2-mmr-19-02-0919){ref-type="fig"}). After BLAST detection, the sequencing results of the clones revealed that the sequence identity was 828/828 (100%) and the target gene lentiviral vector had been successfully constructed ([Fig. 3](#f3-mmr-19-02-0919){ref-type="fig"}).

### TSG-6 expression in KFs following infection

To determine the efficiency of transfection in KFs, total RNA was extracted and RT-PCR was performed. The data indicated that a high level of TSG-6 mRNA expression was detected in the pLVX-Puro-TSG-6 group compared with the KF and Plvx-Puro groups (P\<0.05), while there was no significant difference between the pLVX-Puro group and the KF group (P\>0.05). This suggested that the exogenous TSG-6 gene was transduced successfully ([Fig. 4](#f4-mmr-19-02-0919){ref-type="fig"}). To further verify this result, TSG-6 protein expression was determined using western blot analysis. The results suggested that the expression of TSG-6 protein was increased significantly in the pLVX-Puro-TSG-6 group compared with the pLVX-Puro group and the KF group (P\<0.05), while there was no significant difference between the pLVX-Puro group and the KF group (P\>0.05; [Fig. 5](#f5-mmr-19-02-0919){ref-type="fig"}).

### TSG-6 overexpression inhibited cell proliferation

Cell viability was determined using an MTT assay. Compared with the control and pLVX-Puro group, the proliferation of the TSG-6 transfected cells was significantly decreased. However, there was no significant difference between the pLVX-Puro group and the KF group, which demonstrated that the vector itself had no effect on the viability of KFs ([Fig. 6](#f6-mmr-19-02-0919){ref-type="fig"}).

### Overexpression of TSG-6 induced apoptosis of KFs

Flow cytometry was performed to determine the rate of cell apoptosis. Apoptosis was analyzed by double-staining with Annexin V-FITC and PI. The apoptosis rate in the pLVX-Puro-TSG-6 group was 51.92%, which was significantly higher than that in pLVX-Puro group (19.00%) and the KF group (3.59%; P\<0.05). There was no significant difference in apoptosis rate between the pLVX-Puro group and the KF cell group ([Fig. 7](#f7-mmr-19-02-0919){ref-type="fig"}).

### TSG-6 regulated expression of genes and proteins involved in proliferation, cell cycle and apoptosis

Whether the regulation of TSG-6 affects proteins involved in proliferation, apoptosis and cell cycle in KFs was investigated. Total cellular mRNA or protein was isolated from cells transfected with pLVX-Puro-TSG-6 or pLVX-Puro, and untransfected cells. Flow cytometry analysis suggested that cells were arrested in G2/M phase by TSG-6 overexpression ([Fig. 8](#f8-mmr-19-02-0919){ref-type="fig"}). Levels of p21, cyclin D1, Bax, Bcl-2, caspase-3 and NF-κB were determined by RT-PCR and western blot. The RT-PCR results indicated that transfection of TSG-6 led to an increase in the expression of p21, Bax and caspase-3. Additionally, overexpression of TSG-6 decreased the mRNA levels of cyclin D1 and NF-κB ([Fig. 9](#f9-mmr-19-02-0919){ref-type="fig"}). The ratio of Bcl-2/Bax was also decreased significantly in the TSG-6-transfected cells compared with the control group. Similar results were confirmed by western blot; overexpressed TSG-6 markedly increased the protein levels of p21, Bax and caspase-3 ([Fig. 10](#f10-mmr-19-02-0919){ref-type="fig"}).

Discussion
==========

Keloid formation occurs when the normal wound-healing process is disordered and the evolving scar remains in the proliferative phase of healing. The scar may grow beyond the boundaries of the original wound ([@b13-mmr-19-02-0919]). It has been identified that apoptosis may be a mechanism by which granulation tissue develops, thus decreasing cellularity and scar formation ([@b14-mmr-19-02-0919]). The mRNA expression of TSG-6 in keloid was previously compared with normal skin and it was demonstrated that low expression of TSG-6 may participate in the formation of keloid. The previous investigations indicated that the expression level of TSG-6 in primary keloid fibroblasts derived from individual patients was significantly higher than in normal skin ([@b15-mmr-19-02-0919]), which is supported by the results and conclusions of the present study.

TSG-6 is a hyaluronic acid (HA)-binding protein composed of a single-strand module of two α-helices and two triple-strand β-sheets arranged around a large hydrophobic core ([@b16-mmr-19-02-0919]). TSG-6 is involved in the regulation of leukocyte migration and the pattern of expression indicates that it may be associated with extracellular matrix remodeling ([@b17-mmr-19-02-0919]) Increased TSG-6 protein expression has been detected in the synovial fluid of patients with arthritis, and recombinant TSG-6 protein has been identified to have potent anti-inflammatory effects *in vivo* ([@b18-mmr-19-02-0919]). It has been indicated that TSG-6 is part of a cytokine-initiated feedback loop that reduces the inflammatory response. TSG-6 was observed to form a stable, possibly covalent, 120 kDa complex with a serine protease inhibitor and inter-α inhibitor (IαI) ([@b19-mmr-19-02-0919]). Furthermore, anti-plasmin activity was significantly increased by this complex compared with IαI alone ([@b20-mmr-19-02-0919]). In conclusion, TSG-6 may be a key factor involved in regulating leukocyte migration and matrix remodeling, caused by break down of latent metalloproteinases in the extracellular matrix via enhanced activity of plasmin.

In the current study, a lentiviral vector carrying the TSG-6 gene was transfected into KFs, and increased the expression of TSG-6 mRNA confirmed that the transduction was effective. In addition, western blot results indicated that the TSG-6 protein in the pLVX-Puro-TSG-6 group was primarily encoded by the exogenous TSG-6 gene. To determine whether TSG-6 has selective cytotoxic activity in KFs, MTT and apoptosis assays were performed, and the mRNA and protein levels of key molecules were determined. According to the MTT results, TSG-6 inhibited KF proliferation selectively compared with the negative control. Flow cytometry analysis suggested that TSG-6 selectively induced KF cell death and accumulation of cells in G2/M phase by preventing KFs from entering M phase. RT-PCR and western blot results also supported these conclusions.

Recent studies have revealed that keloids have tumor-like biological functions, and the roles of therapeutic strategies such as microRNAs, bone morphogenetic proteins, activin membrane bound inhibitor and heat shock protein 70 in keloids have been investigated ([@b21-mmr-19-02-0919]--[@b23-mmr-19-02-0919]). It has been confirmed that TSG-6 is lowly expressed in prostate cancer and can be a potential marker for prostate cancer diagnosis ([@b24-mmr-19-02-0919]). A previous study identified that TSG-6 combined with Yeast Cytosine Deaminase and 5-Fluorocytosine exerts anti-tumor effects ([@b25-mmr-19-02-0919]). Pathogenic mechanisms of keloid have not been elucidated in detail; however, controlling fibroblast proliferation and apoptosis via certain targeted genes may be an effective therapeutic strategy for treating keloids. In the current study, TSG-6 overexpression increased apoptosis and decreased cell proliferation, which could offer a protective effect against keloid development.

In summary, KFs transfected with a lentiviral vector carrying TSG-6 expressed a high level of exogenous TSG-6. Transduction of the pLVX-Puro-TSG-6 selectively suppressed proliferation and induced apoptosis in KFs, which confirmed the role of TSG-6 in KFs. As a result, TSG-6 has potential as a gene therapy candidate for the treatment of keloid, and may result in novel and effective therapeutic approaches.
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###### 

Patient information.

  Patient number   Sex      Age   Position        Cause of scar
  ---------------- -------- ----- --------------- ---------------
  01               Male     03    Anterior neck   Scald
  02               Female   05    Chest           Scald
  03               Female   06    Shoulder        Burn
  04               Female   09    Back            Surgery
  05               Male     14    Chest           Burn
  06               Female   18    Earlobe         Puncture
  07               Female   19    Earlobe         Puncture
  08               Male     23    Upper Arm       Surgery
  09               Female   25    Abdomen         Surgery
  10               Female   27    Earlobe         Puncture

###### 

Oligonucleotides used in reverse-polymerase chain reaction analysis.

  Gene        Forward ([@b5-mmr-19-02-0919]--[@b3-mmr-19-02-0919])   Reverse ([@b5-mmr-19-02-0919]--[@b3-mmr-19-02-0919])
  ----------- ------------------------------------------------------ ------------------------------------------------------
  p21         CGTGAGCGATGGAACTTCGA                                   CTCTTGGAGAAGATCAGCCG
  Cyclin D1   CCCTCGGTGTCCTACTTCA                                    CTCCTCGCACTTCTGTTCCT
  Bax         GACGGCCTCCTCTCCTACTT                                   CTCAGCCCATCTTCTTCCAG
  Bcl-2       GAACTGGGGGAGGATTGTGG                                   CCGTACAGTTCCACAAAGGC
  Caspase-3   TGGAATTGATGCGTGATGTT                                   GTCGGCATACTGTTTCAGCA
  NF-κB       AAGATCAATGGCTACACAGG                                   CCTCAATGTCCTCTTTCTGC
  β-actin     CTCCATCCTGGCCTCGCTGT                                   GCTGTCACCTTCACCGTTCC

Bax, apoptosis regulator Bcl-2-associated X protein; Bcl-2, apoptosis regulator B-cell lymphoma-2; NF-κB, nuclear factor-κB.

[^1]: Contributed equally
